Sun Pharma to Acquire Organon in $11.75B Deal
India-based Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion.
Author
Deals and business correspondent
Clara Ashworth covers biopharma mergers, acquisitions, licensing deals and corporate strategy for PharmaWire, from big-pharma takeovers to early-stage China out-licensing.
India-based Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion.
Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation in an all-cash deal valued at approximately $739mn, doubling the size of its biotech royalty portfolio and cementing its position as one of the dominant aggregators in a…
Catalyst Pharmaceuticals, the US rare-disease drug developer, has emerged as a potential acquisition target for Italy's Angelini Pharma, in the latest sign of how aggressively European drugmakers are scouring the US market for…
A wave of analyst downgrades has hit Terns Pharmaceuticals after Merck agreed to acquire the US biotech for $6.7bn, ending one of the most striking small-cap rallies of the past year and underlining the willingness of large pharmaceutical…
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at $6.3bn upfront, as the US drugmaker deepens its push into neuroscience and sleep-related disorders.
Researchers at the University of Wisconsin–Madison have developed a method to simplify the formation of carbon–nitrogen (C–N) bonds, a fundamental step in producing amines widely used in pharmaceuticals, agrochemicals and advanced…
The global market for branded generics is expanding rapidly, reflecting mounting pressure on healthcare systems to contain costs while maintaining patient confidence in treatment quality.
South Korea has consolidated its position as a leading player in pharmaceutical innovation, ranking third globally for drug development pipelines in 2026, behind only the US and China, according to industry data.
Pharmacies warn of supply constraints as freight costs double and petrochemical inputs tighten
Acquisition creates integrated biosimilars platform as wave of biologic patent expiries approaches
AI-integrated facility near Research Triangle Park marks group's largest ever capital outlay
Improved Pharma, the West Lafayette-based pharmaceutical research and consulting group, will present new work on detecting crystalline impurities in amorphous drug formulations at the Spring Pharmaceutical Synchrotron-XRPD Workshop in…
NEUVIOR Pharmaceuticals, a York-based start-up, has secured a feasibility grant from Innovate UK to develop a process for converting pharmaceutical manufacturing waste into bio-based, recyclable materials, in the latest sign of mounting…
Amazon Filters, the Surrey-based process filtration manufacturer, will use this week's ISPE Europe Annual Conference in Copenhagen to pitch its sanitary filtration systems to pharmaceutical and biopharmaceutical buyers, in a bid to deepen…
OliX Pharmaceuticals, the Seoul-listed RNA interference specialist, has signed a memorandum of understanding with Galux, a South Korean artificial-intelligence drug discovery firm, to co-develop a new class of siRNA delivery platform — the…
Disruption linked to tensions involving Iran is rippling through global pharmaceutical supply chains, raising costs and exposing structural vulnerabilities in the United States medicines market.
Merck & Co. has agreed to acquire Terns Pharmaceuticals for $6.7bn, as it seeks to strengthen its oncology pipeline ahead of looming patent expiries on its top-selling drug Keytruda.
Pharmaceutical supply chains are under renewed strain as disruption in the Middle East forces widespread rerouting of air and sea freight, delaying shipments and tightening capacity across global trade routes.
Novo Nordisk has struck a partnership with OpenAI to deploy advanced artificial intelligence across its global operations, in a move that underscores the pharmaceutical industry’s accelerating shift towards AI-led drug development.